No results for ‘’
Shree Ganesh Biotech India Ltd
₹0.60
(0%)
Thu, 11 Jun 2026, 02:43 am
Process Industries
Agricultural Commodities/Milling
24.5KShree Ganesh Biotech India EV/EBITDA Ratio
| Particulars | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 133.63 | 1100 | 750 | 73.34 | 19.96 | 67.31 | 128.57 |
| Price to book ratio | 4.18 | 4.52 | 4.09 | 3.07 | 0.65 | 0.66 | 0.57 |
| Price to sales ratio | 40.76 | 104.93 | 13.72 | 2.55 | 0.65 | 2.06 | 1.56 |
| Price to cash flow ratio | 0 | 0 | 99.89 | 51.97 | 3.86 | 4.12 | 0 |
| Enterprise value | 239Cr | 260Cr | 236Cr | 185Cr | 40.18Cr | 41.43Cr | 35.86Cr |
| Enterprise value to EBITDA ratio | 133.57 | 1090 | 333.77 | 53.73 | 18.69 | 0 | 0 |
| Debt to equity ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Return on equity % | 0 | 0.41 | 0.55 | 4.28 | 3.32 | 0.99 | 0.44 |
Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio
The Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Shree Ganesh Biotech India Ltd's valuation, profitability, and overall financial performance. Tracking the Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Shree Ganesh Biotech India Ltd (NSE: , BSE: 539470) is currently trading at ₹0.60, with a market capitalization of ₹23.92Cr. As a leading company in the Process industries sector and Agricultural commodities/Milling industry, monitoring the Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio Current Value
The current Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio stands at 0.
The Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio remains stable, indicating consistent financial performance.
Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 0
- 2023: 0
- 2022: 18.69
- 2021: 53.73
- 2020: 333.77
The decline in Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Shree Ganesh Biotech India Ltd.
Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Shree Ganesh Biotech India Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.